Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | President and CFO | June 22, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 19,787,969 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 19,787,969 · Balance 19,787,969 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on July 22, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on July 22, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 30, 2023 20:34 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 19,787,969 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-040338 · doc4.xml · derivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,787,969 Underlying: Common Stock · 19,787,969 shares Expires 2033-06-22 F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on July 22, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 23:20 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 640,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001209191-23-012875 · doc4.xml · derivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 Underlying: Common Stock · 640,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 23:34 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-22-047648 · doc4.xml · derivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2032-08-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 22:30 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 75,000 | $2.08 | $156,000.00 |
DisclosureSEC source: 0001209191-22-018941 · doc4.xml · nonDerivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,372 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:50 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-011704 · doc4.xml · derivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 01:37 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 50,000 | $3.72 | $186,000.00 |
DisclosureSEC source: 0001209191-21-069349 · doc4.xml · nonDerivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,372 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 21:21 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 7,200 | $6.72 | $48,399.84 |
DisclosureSEC source: 0001209191-21-052272 · doc4.xml · nonDerivative · entry 3 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,372 F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 21:21 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 23,392 | $6.50 | $151,984.84 |
DisclosureSEC source: 0001209191-21-052272 · doc4.xml · nonDerivative · entry 2 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,172 F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:21 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 9,780 | $6.37 | $62,275.13 |
DisclosureSEC source: 0001209191-21-052272 · doc4.xml · nonDerivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,780 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:12 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001209191-21-046007 · doc4.xml · derivative · entry 1 Alspaugh Jonathan · CIK 0001868112 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-07-05 F1 · derivative.exercise_date: The options will vest as to 1/4th of the total shares on July 6, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on July 6, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.